OptimizeRx Balance Sheet Health
Financial Health criteria checks 5/6
OptimizeRx has a total shareholder equity of $116.3M and total debt of $32.5M, which brings its debt-to-equity ratio to 27.9%. Its total assets and total liabilities are $167.8M and $51.5M respectively.
Key information
27.94%
Debt to equity ratio
US$32.49m
Debt
Interest coverage ratio | n/a |
Cash | US$16.57m |
Equity | US$116.27m |
Total liabilities | US$51.50m |
Total assets | US$167.77m |
Recent financial health updates
We Think OptimizeRx (NASDAQ:OPRX) Has A Fair Chunk Of Debt
Mar 08Does OptimizeRx (NASDAQ:OPRX) Have A Healthy Balance Sheet?
Nov 16OptimizeRx (NASDAQ:OPRX) Is Carrying A Fair Bit Of Debt
Jul 30Recent updates
Even With A 33% Surge, Cautious Investors Are Not Rewarding OptimizeRx Corporation's (NASDAQ:OPRX) Performance Completely
May 09A Subscription Model And EHR Network Will Reshape Healthcare
Transitioning to a subscription-based model aims to enhance revenue predictability and improve net margins with recurring income.Is OptimizeRx Corporation (NASDAQ:OPRX) Expensive For A Reason? A Look At Its Intrinsic Value
Apr 06We Think OptimizeRx (NASDAQ:OPRX) Has A Fair Chunk Of Debt
Mar 08At US$6.29, Is It Time To Put OptimizeRx Corporation (NASDAQ:OPRX) On Your Watch List?
Feb 14Market Might Still Lack Some Conviction On OptimizeRx Corporation (NASDAQ:OPRX) Even After 30% Share Price Boost
Dec 15Does OptimizeRx (NASDAQ:OPRX) Have A Healthy Balance Sheet?
Nov 16OptimizeRx (NASDAQ:OPRX) Is Carrying A Fair Bit Of Debt
Jul 30OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors
Jan 09Analyst Forecasts Just Became More Bearish On OptimizeRx Corporation (NASDAQ:OPRX)
Aug 24OptimizeRx Corporation (NASDAQ:OPRX) Shares May Have Slumped 38% But Getting In Cheap Is Still Unlikely
Aug 16Is Now An Opportune Moment To Examine OptimizeRx Corporation (NASDAQ:OPRX)?
May 31OptimizeRx: A Top Candidate For My Speculative 'Bio Boom' Portfolio
Oct 12Is Now The Time To Look At Buying OptimizeRx Corporation (NASDAQ:OPRX)?
Sep 23OptimizeRx extends reach with Cooler Screens Partnership
Jul 26OptimizeRx: A Small-Cap Digital Health Technology Gem With Near-Term Inflection In Profitability
Jun 27Financial Position Analysis
Short Term Liabilities: OPRX's short term assets ($51.7M) exceed its short term liabilities ($18.4M).
Long Term Liabilities: OPRX's short term assets ($51.7M) exceed its long term liabilities ($33.1M).
Debt to Equity History and Analysis
Debt Level: OPRX's net debt to equity ratio (13.7%) is considered satisfactory.
Reducing Debt: OPRX's debt to equity ratio has increased from 0% to 27.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable OPRX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: OPRX is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 19.8% per year.
Discover healthy companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/06/20 14:20 |
End of Day Share Price | 2025/06/20 00:00 |
Earnings | 2025/03/31 |
Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OptimizeRx Corporation is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Kyle Bauser | B. Riley Securities, Inc. |
Anderson Schock | B. Riley Securities, Inc. |
Constantine Davides | Citizens JMP Securities, LLC |